The FDA has approved Indianapolis-based Eli Lilly and Co.'s Emgality (galcanezumab-gnlm) solution (300 mg) for injection for treating episodic cluster headache in adults, making it the first and only calcitonin gene-related peptide (CGRP) inhibitor that reduces the frequency of these attacks.